Product Name:BPC-157
Cas No:137525-51-0
Molar Mass:1419.54
Chemical Formula:C62H98N16O22
Synonyms:Bepecin, PL 14736
Storage:Store at -20°C
Sequence:GEPPPGKPADDAGLV
Target Indicators:unknown
Purity:98%
Application:BPC-157, or Body Protection Compound-157, is a synthetic peptide derived from a portion of human gastric juice protein. It exhibits remarkable regenerative properties and has been extensively studied for its potential therapeutic applications in various fields. In pharmaceutical chemistry, BPC-157 is investigated for its ability to promote tissue repair, accelerate wound healing, and reduce inflammation. It interacts with multiple cellular signaling pathways involved in tissue regeneration, including the promotion of angiogenesis and the modulation of growth factor expression. BPC-157 has shown promising results in preclinical studies for treating musculoskeletal injuries, such as tendon and ligament damage, as well as gastrointestinal disorders, including inflammatory bowel disease. Its wide-ranging therapeutic effects make it a valuable candidate for developing novel treatments in regenerative medicine, sports medicine, and gastroenterology.
Current Research:Our research delves into the profound impact of sotalol-induced occlusion-like syndrome, a condition aggravated by antiarrhythmics like class II and class III antiarrhythmics and beta-blockers. We’ve explored the therapeutic potential of the cytoprotective stable gastric pentadecapeptide BPC-157 in addressing arrhythmia-related issues, including those arising from sotalol usage. BPC-157’s broad-spectrum action on striated, smooth, and heart muscle presents a promising avenue for treating various heart disturbances, myocardial infarction, heart failure, pulmonary hypertension, arrhythmias, and thrombosis presentations.
Notably, while sotalol usage may exacerbate occlusion-like syndrome, our studies suggest that BPC-157 administration could provide a unique therapeutic approach. Unlike sotalol, which may further impair the beta-adrenergic system, BPC-157 application demonstrates a special therapeutic effect by activating collateral pathways, such as the azygos vein, thus circumventing occlusion-related issues. Our findings indicate that BPC-157 effectively resolves a wide range of occlusion/occlusion-like syndromes and multiple organ failures, irrespective of the underlying cause that compromises endothelial function.
Furthermore, our research underscores BPC-157’s rapid counteraction against specific injuries and challenges, including vessel occlusion, adrenergic system stimulants, and receptor blockers. This cytoprotective peptide enhances endothelium function, activates collateral pathways, and attenuates arrhythmias, thereby restoring normal physiological processes.
Importantly, BPC-157’s therapeutic efficacy extends beyond cardiovascular issues, as evidenced by its positive effects in ulcerative colitis trials and its ability to counteract leaky gut syndrome and act as a free radical scavenger. Moreover, its modulation of the NO-system and activation of molecular pathways contribute to its cytoprotective properties, making it a promising candidate for treating a wide array of conditions beyond arrhythmias.
In conclusion, our research highlights the potential of BPC-157 as a novel therapeutic agent for managing sotalol-induced occlusion-like syndrome and related cardiovascular complications. Its cytoprotective mechanisms, vascular recovery capabilities, and broad-spectrum action make it a promising candidate for further clinical investigation and eventual implementation in medical practice.
